SCHEDULE: OrbiMed Boosts NeuroPace Stake to 4.4%

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC collectively report a 4.4% ownership in NeuroPace, Inc. common stock as of June 30, 2026.

Summary

• OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have jointly filed an amendment to their Schedule 13G, reporting their beneficial ownership of NeuroPace, Inc. common stock.
• The total aggregate amount beneficially owned by these entities is 1,505,125 shares.
• This represents 4.4% of the class of securities.
• Both entities share the power to vote or direct the vote, and the power to dispose or direct the disposition of these shares.
• The filing is an amendment (Amendment No. 8) to a previous filing, dated June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not dominant ownership stake by OrbiMed, indicating continued investor interest without immediate takeover implications.

Positives

• OrbiMed, a significant healthcare-focused investment firm, continues to hold a substantial stake in NeuroPace, indicating ongoing confidence in the company's prospects.
• The shared voting and dispositive power suggests a coordinated investment strategy by OrbiMed entities.

Negatives

• The filing does not disclose any new capital raises or significant strategic shifts by the company itself, focusing solely on OrbiMed's ownership.

Risks

• While OrbiMed's stake is significant, it does not represent a controlling interest, meaning the company's strategic direction may still be influenced by other major shareholders or management.
• The filing does not provide insights into the specific reasons for OrbiMed's investment level or any potential future changes to their holdings.

Future Outlook

This filing pertains to ownership and does not contain forward-looking statements or guidance from NeuroPace, Inc. regarding its business operations or financial performance.

Management Comments

• Carl L. Gordon, as Member of OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, certified that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that OrbiMed is a prominent investor in the healthcare and life sciences sectors. Their continued reporting on NeuroPace, a company focused on neuromodulation devices, suggests sustained interest in the medical technology space, particularly in companies developing innovative treatments for neurological conditions.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports on beneficial ownership thresholds (typically 5% or more) for institutional investors. It does not contain operational or financial performance data for direct comparison to industry peers.
• OrbiMed's reported 4.4% stake is a significant holding for an institutional investor, often indicating a substantial conviction in the company's long-term value, but it is below the 5% threshold that typically triggers more detailed Schedule 13D filings unless other control-related factors are present.

Stakeholder Impact

• Shareholders: The continued significant investment by OrbiMed may be viewed positively, suggesting external validation of the company's potential.
• Management: The filing confirms that OrbiMed does not intend to influence or change control of the issuer, allowing management to continue its operational strategy.
• Creditors: No direct impact is indicated by this ownership filing.

Next Steps

• OrbiMed will continue to monitor its investment in NeuroPace, Inc.
• Future amendments to Schedule 13G will be filed if ownership levels change significantly or if circumstances warrant a shift to a Schedule 13D filing.

Key Dates

Keywords

NeuroPace, OrbiMed, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Healthcare Investment